A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor

Checkpoint inhibitor immunotherapies have had major success in treating patients with late-stage cancers, yet the minority of patients benefit. Mutation load and PD-L1 staining are leading biomarkers associated with response, but each is an imperfect predictor. A key challenge to predicting response...

Descripción completa

Detalles Bibliográficos
Autores principales: Leiserson, Mark D. M., Syrgkanis, Vasilis, Gilson, Amy, Dudik, Miroslav, Gillett, Sharon, Chayes, Jennifer, Borgs, Christian, Bajorin, Dean F., Rosenberg, Jonathan E., Funt, Samuel, Snyder, Alexandra, Mackey, Lester
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312275/
https://www.ncbi.nlm.nih.gov/pubmed/30596661
http://dx.doi.org/10.1371/journal.pone.0208422

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312275/
https://www.ncbi.nlm.nih.gov/pubmed/30596661
http://dx.doi.org/10.1371/journal.pone.0208422

Ejemplares similares